Health and Fitness Health and Fitness
Thu, January 6, 2011
[ Thu, Jan 06th 2011 ] - Market Wire
Bond Labs Signs Maryland Distributor for Resurrectiona" Anti-Hangover
[ Thu, Jan 06th 2011 ] - Market Wire
Humana Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Thu, Jan 06th 2011 ] - Market Wire
Cambridge Heart to Present at OneMedForum San Francisco 2011
[ Thu, Jan 06th 2011 ] - Market Wire
Celgene verffentlicht aktuelle Informationen ber Zulassungsverfahren
[ Thu, Jan 06th 2011 ] - Market Wire
Chemed Corporation to Present at the29th Annual J.P. Morgan Healthcare Conference
[ Thu, Jan 06th 2011 ] - Market Wire
Vertex Pharmaceuticals Announces Webcast of its P .. the 29th Annual J.P. Morgan Healthcare Conference
[ Thu, Jan 06th 2011 ] - Market Wire
SurModics and Ramius Reach Agreement Regarding 2011 Annual Meeting of Shareholders
[ Thu, Jan 06th 2011 ] - Market Wire
XIFAXAN® 550 mg Tablets Demonstrated Significant .. Irritable Bowel Syndrome Without Constipation Ac
[ Thu, Jan 06th 2011 ] - Market Wire
Covidien Announces the Availability of Nellcora" .. with Drger Infinity® Acute Care System in Europe
[ Thu, Jan 06th 2011 ] - Market Wire
Celgene annonce le d©p't de soumissions r©glementaires
[ Thu, Jan 06th 2011 ] - Market Wire
Biogen Idec nomina Doug Williams responsabile del .. Steven Holtzman a capo del Corporate Development
[ Thu, Jan 06th 2011 ] - Market Wire
Covidien kondigt beschikbaarheid aan van Nellcora .. met Drger Infinity® Acute Care System in Europa
[ Thu, Jan 06th 2011 ] - Market Wire
Covidien annuncia la disponibilit della tecnologi .. l'Infinity® Acute Care System di Drger in Europa
[ Thu, Jan 06th 2011 ] - Market Wire
Biogen Idec ernennt Doug Williams zum Leiter der .. bteilung und Steven Holtzman zum Leiter der Unter
[ Thu, Jan 06th 2011 ] - Market Wire
Covidien meldet die Verfgbarkeit der Nellcora" Ox .. standteil des Infinity® Acute Care Systems von D
[ Thu, Jan 06th 2011 ] - Market Wire
Biogen Idec stelt Doug Williams aan als hoofd O&O .. n Steven Holtzman als hoofd Corporate Development
Wed, January 5, 2011
[ Wed, Jan 05th 2011 ] - Market Wire
Santarus and Depomed Announce Availability of GLUMETZA 500 mg Tablets
[ Wed, Jan 05th 2011 ] - Market Wire
SuperGen Announces Enrollment of First Patient in .. in Human Trial of SGI-110 in MDS and AML Patients
[ Wed, Jan 05th 2011 ] - Market Wire
ANGIOTECH PHARMACEUTICALS ANNOUNCES NOTICE OF DELISTING FROM THE NASDAQ STOCK MARKET
[ Wed, Jan 05th 2011 ] - Market Wire
Positive Phase II Results with Iniparib (BSI-201) .. ple Negative Breast Cancer Published in The New E
[ Wed, Jan 05th 2011 ] - Market Wire
Medtronic Announces $750,000 in Funding to Support Healthcare Infrastructure Development in Haiti
[ Wed, Jan 05th 2011 ] - Market Wire
Hythiam Announces Catasys Contract with Coventry Health Care, Inc. Unit
[ Wed, Jan 05th 2011 ] - Market Wire
CEO of ARCA biopharma to Speak on Cardiovascular .. Medicine at Personalized Medicine Coalition Confe
[ Wed, Jan 05th 2011 ] - Market Wire
St. Jude Medical Announces Fourth Quarter and Full-Year 2010 Earnings Conference Call
[ Wed, Jan 05th 2011 ] - Market Wire
LabCorp is Scheduled to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
LifePoint Hospitals to Participate in 29th Annual J.P. Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Almirall and Forest Announce Positive Results fro .. of Aclidinium Bromide and the Phase IIb Studies w
[ Wed, Jan 05th 2011 ] - Market Wire
AngioDynamics Reports Fiscal 2011 Second Quarter Financial Results
[ Wed, Jan 05th 2011 ] - Market Wire
Alkermesa? Corporate Presentation to be Webcast at the JPMorgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Celgene ofrece nuevos datos sobre presentaciones normativas

Celgene ofrece nuevos datos sobre presentaciones normativas


Published on 2011-01-05 09:30:59 - Market Wire
  Print publication without navigation


BOUDRY, Suiza--([ BUSINESS WIRE ])--Celgene International Srl (NASDAQ: CELG) ha anunciado presentaciones normativas para sus terapias contra el cncer hematolgico REVLIMID (lenalidomida) y ISTODAX (romidepsin).

La empresa ha presentado una solicitud de autorizacin para la comercializacin (MAA en sus siglas en ingl©s) para la aprobacin de REVLIMID (lenalidomida) para el tratamiento de mantenimiento de pacientes con mieloma mltiple de reciente diagnstico que no han progresado tras el tratamiento inicial con melfaln, prednisona y REVLIMID o tras un transplante autlogo de c©lulas madre. La solicitud se ha entregado a la Agencia Europea de Medicamentos (EMA) el 31 de diciembre, 2010.

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.

Contributing Sources